title: Characterization and detection of cellular and proteomic alterations in stable stathmin-overexpressing, taxol-resistant BT549 breast cancer cells using offgel IEF/PAGE difference gel electrophoresis.
abstract: Stathmin/oncoprotein 18, a protein that regulates microtubule dynamics, is highly expressed in a number of tumors including leukemia, lymphoma, neuroblastoma, breast, ovarian, and prostate cancers. High stathmin levels have been associated with the development of resistance to the widely used anti-cancer drug taxol ((®)Taxol, paclitaxel). The mechanisms of stathmin-mediated taxol resistance are not well-understood at the molecular level. To better understand the role of stathmin in taxol resistance, we stably overexpressed stathmin twofold in BT549 human breast cancer cells and characterized several cell processes involved in the mechanism of action of taxol. After stable overexpression of stathmin, neither the cell doubling time nor the mitotic index was altered and the microtubule polymer mass was reduced only modestly (by 18%). Unexpectedly, microtubule dynamicity was reduced by 29% after stathmin overexpression, resulting primarily from reduction in the catastrophe frequency. Sensitivity to taxol was reduced significantly (by 44%) in a clonogenic assay, and stathmin appeared to protect the cells from the spindle-damaging effects of taxol. The results suggest that in the stably stathmin-overexpressing clones, compensatory gene expression occurred that resulted in normal rates of cell proliferation and prevented the increase in catastrophe frequency expected in response to stathmin. Stathmin overexpression protected the cells from taxol-induced abnormal mitoses, and thus induced taxol resistance. Using offgel IEF/PAGE difference gel electrophoresis, we identified a number of proteins whose expression is reduced in the taxol-resistant stathmin-overexpressing cell lines, including proteins involved in the cytoskeleton and cell structure, the stress response, protein folding, glycolysis, and catalysis.
authors.affiliation: Genomics and Proteomics Core Laboratories, University of Pittsburgh, Pittsburgh, PA, USA.
authors.forename: Manimalha
authors.initials: M
authors.lastname: Balasubramani
authors.forename: Chitose
authors.initials: C
authors.lastname: Nakao
authors.forename: Guy T
authors.initials: GT
authors.lastname: Uechi
authors.forename: John
authors.initials: J
authors.lastname: Cardamone
authors.forename: Kathy
authors.initials: K
authors.lastname: Kamath
authors.forename: Kristen L
authors.initials: KL
authors.lastname: Leslie
authors.forename: Raghavan
authors.initials: R
authors.lastname: Balachandran
authors.forename: Leslie
authors.initials: L
authors.lastname: Wilson
authors.forename: Billy W
authors.initials: BW
authors.lastname: Day
authors.forename: Mary Ann
authors.initials: MA
authors.lastname: Jordan
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D001943:Breast Neoplasms / Q000235:genetics* / Q000378:metabolism; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D015180:Electrophoresis, Gel, Two-Dimensional / Q000379:methods*; D005260:Female; D006801:Humans; D008870:Microtubules / Q000187:drug effects; D008938:Mitosis; D008940:Mitotic Index; D009363:Neoplasm Proteins / Q000187:drug effects; D017239:Paclitaxel / Q000494:pharmacology*; D050777:Stathmin / Q000235:genetics / Q000378:metabolism / Q000502:physiology*; D015854:Up-Regulation
chemical_list: D000970:Antineoplastic Agents; D009363:Neoplasm Proteins; D050777:Stathmin; D017239:Paclitaxel
references.citation: Cancer Res. 2009 Sep 1;69(17):6906-14
references.pmid: 19671798
references.citation: Proteomics. 2003 Oct;3(10):1863-73
references.pmid: 14625848
references.citation: Proteomics. 2009 Mar;9(6):1556-66
references.pmid: 19242932
references.citation: J Cancer Res Clin Oncol. 2009 Feb;135(2):181-9
references.pmid: 18758817
references.citation: Cell. 1996 Feb 23;84(4):623-31
references.pmid: 8598048
references.citation: Proc Natl Acad Sci U S A. 1993 Oct 15;90(20):9552-6
references.pmid: 8105478
references.citation: J Biol Chem. 1997 Mar 28;272(13):8129-32
references.pmid: 9079624
references.citation: Cancer Lett. 2002 Jul 8;181(1):95-107
references.pmid: 12430184
references.citation: J Cell Sci. 1999 Nov;112 ( Pt 21):3713-22
references.pmid: 10523507
references.citation: Cancer Invest. 2000;18(8):722-30
references.pmid: 11107442
references.citation: Biochemistry. 1995 Feb 21;34(7):2203-11
references.pmid: 7857932
references.citation: FEBS Lett. 2009 Jun 5;583(11):1772-84
references.pmid: 19327356
references.citation: EMBO J. 1996 Oct 1;15(19):5290-8
references.pmid: 8895574
references.citation: J Pharmacol Exp Ther. 2009 Apr;329(1):38-47
references.pmid: 19131583
references.citation: J Biol Chem. 1994 Dec 2;269(48):30626-35
references.pmid: 7982983
references.citation: Proteomics. 2007 May;7(9):1549-59
references.pmid: 17366476
references.citation: Oncogene. 2010 Jan 28;29(4):597-607
references.pmid: 19881550
references.citation: Lab Invest. 2005 Mar;85(3):316-27
references.pmid: 15654357
references.citation: Curr Cancer Drug Targets. 2007 Dec;7(8):730-42
references.pmid: 18220533
references.citation: J Proteome Res. 2009 Jul;8(7):3430-8
references.pmid: 19485423
references.citation: Cell Mol Life Sci. 2009 Oct;66(20):3263-76
references.pmid: 19585080
references.citation: J Proteome Res. 2007 Feb;6(2):772-80
references.pmid: 17269733
references.citation: Biochim Biophys Acta. 2009 Feb;1794(2):225-36
references.pmid: 18973835
references.citation: Electrophoresis. 1997 Oct;18(11):2071-7
references.pmid: 9420172
references.citation: Int J Oncol. 2007 Jun;30(6):1545-51
references.pmid: 17487377
references.citation: Proteomics. 2005 Feb;5(3):796-804
references.pmid: 15682461
references.citation: Mol Biol Cell. 2009 Aug;20(15):3451-8
references.pmid: 19515833
references.citation: Br J Cancer. 2000 Jan;82(1):142-50
references.pmid: 10638981
references.citation: Clin Chem Lab Med. 2002 Mar;40(3):221-34
references.pmid: 12005211
references.citation: J Biol Chem. 2006 Jan 27;281(4):2071-8
references.pmid: 16317007
references.citation: Mol Cell Biol. 1997 Jun;17(6):3459-67
references.pmid: 9154845
references.citation: Mol Biol Cell. 1999 Jan;10(1):105-18
references.pmid: 9880330
references.citation: J Cell Biol. 2000 May 15;149(4):767-74
references.pmid: 10811818
references.citation: Cancer Res. 2003 Sep 15;63(18):6026-31
references.pmid: 14522931
references.citation: Oncogene. 2003 Oct 20;22(47):7280-95
references.pmid: 14576838
references.citation: Proteomics. 2008 May;8(9):1744-9
references.pmid: 18442176
references.citation: Biochim Biophys Acta. 2007 Jan;1774(1):93-101
references.pmid: 17085086
references.citation: J Natl Cancer Inst. 1990 Jul 4;82(13):1107-12
references.pmid: 2359136
references.citation: EMBO J. 2000 Feb 15;19(4):572-80
references.pmid: 10675326
references.citation: Cancer Res. 2002 Dec 1;62(23):6864-9
references.pmid: 12460900
references.citation: J Cell Sci. 1998 Nov;111 ( Pt 22):3333-46
references.pmid: 9788875
references.citation: J Cell Biol. 1999 Sep 20;146(6):1289-302
references.pmid: 10491392
references.citation: J Proteome Res. 2009 Apr;8(4):1902-12
references.pmid: 19714814
references.citation: Proteomics. 2009 Jan;9(1):182-93
references.pmid: 19053080
references.citation: Proteomics. 2006 Apr;6(8):2609-25
references.pmid: 16526084